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PERSPECTIVE OPEN
An algorithm recommendation for the pharmacological
management of allergic rhinitis in the UK: a consensus
statement from an expert panel
Brian Lipworth1, Jon Newton2, Bhaskar Ram3, Iain Small4 and Jürgen Schwarze5
Allergic rhinitis is a frequent presenting problem in primary care in the UK, and has increased in prevalence over the last 30 years.
When symptomatic, patients report signiﬁcant reduction in their quality of life and impairment in school and work performance.
Achieving adequate symptom control is pivotal to successful allergic rhinitis management, and relies mostly on pharmacotherapy.
While it is recognised that most mild-moderate allergic rhinitis symptoms can be managed successfully in primary care, important
gaps in general practitioner training in relation to allergic rhinitis have been identiﬁed. With the availability of new effective
combination therapies, such as the novel intranasal formulation of azelastine hydrochloride and ﬂuticasone propionate in a single
device (Dymista®; Meda), the majority of allergic rhinitis symptoms can be treated in the primary care setting. The primary objective
of this consensus statement is to improve diagnosis and treatment of allergic rhinitis in primary care, and offer guidance on
appropriate referral of difﬁcult-to-treat patients into secondary care. The guidance provided herein outlines a sequential treatment
pathway for allergic rhinitis in primary care that incorporates a considered approach to improve the management of allergic rhinitis
symptoms and improve compliance and patient satisfaction with therapy. Adherence with this care pathway has the potential to
limit the cost of providing effective allergic rhinitis management in the UK by avoiding unnecessary treatments and investigations,
and avoiding the need for costly referrals to secondary care in the majority of allergic rhinitis cases. The fundamentals presented in
this consensus article should apply in most health-care settings.
npj Primary Care Respiratory Medicine  (2017) 27:3 ; doi:10.1038/s41533-016-0001-y
INTRODUCTION
The aim of any disease management plan is control of the disease.
In 2015, a multi-professional group of clinicians met in Stirling,
Scotland to discuss the development of a simpliﬁed allergic
rhinitis (AR) treatment algorithm for use in primary and secondary
care, incorporating current knowledge and recently available
treatments. This consensus statement is a result of that initial
meeting and subsequent collaboration among the working party.
The primary objective is to promote better management of AR
patients, improve diagnosis and treatment in primary care and to
facilitate transition of difﬁcult-to-treat patients into secondary
care.
HOW AR CAN AFFECT PATIENTS?
AR a common condition that affects >20% of the UK population, is
a frequent presenting problem in primary care,1,2 and is increasing
in prevalence.3,4 It is associated with considerable morbidity;
signiﬁcantly reducing quality of life,5,6 interfering with attendance
and performance at school and work,7–9 and resulting in
considerable health-care and indirect costs.10–13 Around 50–80%
of AR patients report that their condition interferes with sleep,
resulting in daytime fatigue, decreased alertness, inability to
concentrate, depression and irritability.14 AR is also associated
with a number of coexisting conditions, including asthma,
sinusitis, upper respiratory tract infection, otitis media with
effusion and nasal polyposis.15,16
AR MANAGEMENT IN THE UK
Management of AR is generally not allergen-speciﬁc and relies in
the main on pharmacotherapy to control symptoms.17,18 Most
mild-moderate AR symptoms can be managed successfully in
primary care. However, one-third of general practitioner (GP)
specialty training programmes do not provide allergy training.19
Initial AR monotherapy is failing many patients in the UK.20 A
database survey of 22,000 AR patients living in the UK showed
that the majority of seasonal AR (SAR) and perennial AR (PAR)
patients received monotherapy as their initial prescription of the
season, but such monotherapy (e.g., antihistamine [AH] or
intranasal corticosteroid [INCS]) proved insufﬁcient for many
(20–25% SAR patients; 37–46% of PAR patients). Other patients
started the season on a multi-therapy regimen (33% and 23% of
SAR and PAR patients, respectively) and this proportion increased
during the season. As the number of therapies prescribed
increased, so too did the number of return GP consultations. By
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the end of the season around half of all AR sufferers were
prescribed multiple therapies, most commonly oral AH plus INCS.
However, this combination is not supported by clinical trials of
combination regimens vs. monotherapy.21,22 The Allergic Rhinitis
and its Impact on Asthma (ARIA) guidelines state that “combina-
tion between drugs has been tested, but insufﬁcient data are
available to make a recommendation concerning the combined
use of oral AH and INCS”.23
WHY IT’S IMPORTANT TO GET RHINITIS UNDER CONTROL
The link between AR and asthma is well-established.23,24 Both AR
and non-AR are risk factors for the development of asthma; co-
morbid rhinitis affects up to 75% of those with asthma.24,25 Poor
control of rhinitis predicts poor control of asthma; asthma patients
with signiﬁcant rhinitis are four-times more likely to have poorly-
controlled asthma than those without,24 with a negative impact
on asthma control equivalent to that of smoking.26 Moreover,
failure to treat AR appropriately results in increased asthma
medication use for co-morbid patients.27
ASSESSMENT OF AR CONTROL
Some sophisticated AR control questionnaires have been devel-
oped including the Control of Allergic Rhinitis and Asthma Test28
and Rhinitis Control Assessment Test.29,30 Others advocate a multi-
factorial assessment incorporating an assessment of (i) severity
and/or frequency of daily or nocturnal symptoms, (ii) impairments
in social, physical, professional and educational activities, (iii)
respiratory function monitoring and (iv) exacerbations (e.g.,
unscheduled medical consultations and rescue medication
use).31 Although useful in clinical trials these are unlikely to be
used routinely in day-to-day practice. ARIA has recently recom-
mended a simple visual analogue scale (VAS) as the new language
of AR control, with a score of 5/10 cm used to assess control and
guide treatment decisions as part of a simple algorithm called the
AR clinical decisions support system (CDSS).32 This VAS has also
been incorporated into an app for patients (Allery Diary). A
companion app for physicians is currently under development
(which includes the AR CDSS; Allergy Diary Companion), thus
linking key stakeholders with a common language of AR control.
WHAT AR PATIENTS WANT FROM TREATMENT
Living with symptomatic AR means coping with any or all of the
symptoms of nasal congestion, headache, postnasal drip, repeated
sneezing, runny nose and other symptoms on a near-daily basis.33
AR patients have high expectations from their treatment,34 but
also a high degree of dissatisfaction with AR treatment,35 for
reasons that include: symptom breakthrough, lack of 24-hour
coverage, lack of coverage of both nasal and ocular symptoms,
and unwanted side effects.15 Patients want faster and more
complete symptom control.27 Insufﬁcient symptom control with
INCS and oral AH is a major concern, and a situation, which has
not improved over time.15 Many physicians underestimate AR
severity and consequently fail to issue adequate treatment,36 a
situation which appears to have changed little in a decade.37
MANAGEMENT IN PRIMARY CARE—DIAGNOSIS
The deﬁnition, aetiology and classiﬁcations of AR are described in
Table 1,1,23 and the diagnosis of AR by symptom assessment is
outlined in Fig. 1.23 Conﬁrmation of the diagnosis may be made
through questions concerning family history, social history
(housing, pets, occupation, possible triggers), and visual examina-
tion. The common triggers for AR are listed in Table 1.1
AR is the predominant form of rhinitis in children, but also
accounts for one-third of adult cases.1 At greatest risk are those
with a personal or family history of atopy (deﬁned by positive skin
prick tests or speciﬁc IgE to common aeroallergens).2 The clinical
history should determine whether allergy testing is required,
which may be useful to identify or exclude an allergic trigger that
may inﬂuence management, e.g., aeroallergen avoidance. GPs
should perform either skin prick testing or serum total/speciﬁc IgE
depending on local availability. The former has the advantage that
it is cheaper and the patient gets instant feedback, but is time
consuming and requires stopping anti-histamines for a week.
Ideally, allergy testing would be performed in all patients with
rhinitis not only for advice about potential allergen avoidance but
also because it will alter the management pathway. Allergy testing
will not, however, identify non antigenic chemical irritants which
can cause nasal airway hyper-reactivity through a non IgE-
mediated pathway. Indeed in many cases exogenous chemical
irritants may aggravate underlying AR. In reality, the majority of
patients presenting in primary care with AR can be managed
without formal identiﬁcation of the speciﬁc allergic trigger18 with
pharmacotherapy.
MANAGEMENT IN PRIMARY CARE—TREATMENT
Figure 2a shows an algorithm for the treatment of AR in primary
care, adapted by the consensus group from the 2008 British
Society of Allergy & Clinical Immunology (BSACI) guidelines1 in
order to simplify treatment in primary care and incorporate
recently available treatment options.
Education
Patients should be educated on the nature of AR, allergen avoidance,
available treatments (including safety and potential side effects), and
be given realistic expectations of the results of therapy. Treatment
failure may be related to poor technique in the use of nasal sprays
and drops and, therefore, appropriate training is essential.
Treatment options
Nasal douching. Saline douching is a safe, inexpensive treatment,
demonstrated to reduce symptoms in children and adults with
seasonal rhinitis.38,39 It is more commonly used in mainland
Europe than in the UK. In our opinion it has only a limited role in
the management of AR, and there is little objective data to
support its use.
Oral/topical non-sedating antihistamines. Oral and topical non-
sedating AHs are recommended as ﬁrst-line therapy for mild-
moderate intermittent and mild persistent AR. The therapeutic
effect of intranasal AH is superior to that that of oral AH,40 with
the additional beneﬁt of a faster onset of action (i.e., within
15mins).41 Patients responsive to AH therapy should be instructed
to continue therapy during periods of allergen exposure. Those
non-responsive to therapy (e.g., symptomatic after 2 weeks)
should be stepped up.
Intranasal corticosteroids. INCSs are recommended as ﬁrst-line
therapy for moderate-severe persistent symptoms and treatment
failures with AHs alone. For patients who do not tolerate INCSs or
prefer not to use them, adding a leukotriene receptor antagonist
to an oral or topical AH may be considered.42,43 Responsive
patients should be instructed to continue therapy during periods
of allergen exposure. Those non-responsive to therapy (e.g.,
symptomatic after 4 weeks) should be stepped up.
Recently-approved AR treatment. The combination of intranasal
azelastine hydrochloride (AZE) and ﬂuticasone propionate (FP) in a
single device (Dymista® (INCS/AZE); Meda, Solna, Sweden) is a
novel formulation that is indicated for adults and adolescents ≥12
years with moderate/severe SAR or PAR if monotherapy with
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either INCS or AH is not considered sufﬁcient.44 In primary care,
the consensus group considers that INCS/AZE (single device) may
be used second line after failure of topical INCS after checking for
the correct use and compliance with medication. If incorrect use
or non-compliance is found, re-education followed by repeat trial
of topical INCS is recommended before INCS/AZE (single device)
prescription. Alternatively, the addition of an oral AH to INCS may
be considered in the case of INCS monotherapy failure, particularly
for children <12 years for whom INCS/AZE (single device) is not
yet indicated. However, it should be noted that the evidence to
support this practice is lacking.21,45
INCS/AZE (single device) may be used ﬁrst line in certain cases
in which the GP considers that monotherapy is more likely to fail,
if they consider it warranted in their professional opinion, in
accordance with the labelled product indication.44 This recom-
mendation is based on an extensive review of existing clinical trial
evidence,46–49 and data obtained in routine clinical practice in
several countries in Europe including Germany, Sweden, Denmark,
Norway and Romania.50 INCS/AZE (single device) is recommended
ﬁrst-line in the recently published AR CDSS from ARIA for those
patients with a VAS score >5/10 cm.32 The speed of onset with
INCS/AZE (single device) for both nasal and ocular symptom relief
and the use of a single spray may improve compliance and
treatment outcomes by avoiding administration and delivery
issues.51
Oral corticosteroids. This consensus group does not recommend
routine early use of oral corticosteroids (OC), which should be
reserved for short-term acute severe symptoms, in combination
with a topical INCS or AZE/INCS (single device). A suggested
regime for adults is 0.5 mg/kg given orally in the morning for
5–10 days.1
Referral
In the event of treatment failure on second-line INCS/AZE (single
device) in primary care, checking for the correct use of medication,
compliance, and whether the correct diagnosis was made is
advised. Following that, referral to secondary care is recom-
mended for further investigations.
Management in secondary care
In secondary care, the consensus group considers that INCS/AZE
(single device) could be used as a ﬁrst-line alternative to topical
INCS in patients with moderate-severe symptoms (Fig. 2b). This is
in contrast to primary care where high bioavailability INCS (e.g.,
beclomethasone dipropionate) ﬁrst line is often prescribed based
on formulary recommendation and acquisition cost rather than on
efﬁcacy, safety or patient-reported outcomes. The consensus
group, however, had a preference for modern, low bioavailability
Fig. 1 Diagnosis of allergic rhinitis through symptom assessment. Adapted from ARIA Bousquet 2008.23 IgE: immunoglobulin E; ENT: Ear Nose
Throat; CT: computed tomography
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steroids (e.g., budesonide; FP, ﬂuticasone furoate or mometasone
furoate).
Symptom-speciﬁc investigations for refractory symptoms
should be completed in secondary care following INCS/AZE
(single device). Add-on therapy with symptom-speciﬁc treatment
such as ipratropium for watery rhinorrhoea, or oral AH for nasal
itching/sneezing may be reserved for use in secondary care. It
should be noted that currently there is no scientiﬁc evidence to
support this practice.21,45 In the event of INCS/AZE (single device)
failure, the consensus group recommended adding OC for
Allergic rhinitis treatment algorithm: expert consensus
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Fig. 2 Treatment algorithm for allergic rhinitis in (a) primary care and (b) secondary care. AH: anti-histamine; AZE: azelastine; IgE:
immunoglobulin E; INCS: intranasal corticosteroid; LTRA: leukotriene receptor antagonist; OAH: oral antihistamine; OC: oral corticosteroid; Rx:
treatment; SPT: skin prick test; Sx: symptoms. (a) *You may consider the addition of an OAH to INCS. However, scientiﬁc evidence shows that
adding an OAH to INCS provides no additional beneﬁt over INCS alone.21, 45 †This consensus group does not recommend routine early use of
oral corticosteroids (OC); OC use should be reserved for short-term acute severe symptoms. (b) *Evidence for the beneﬁt of these add-ons is
lacking. Adapted from BSACI Scadding 2008.1
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7–14 days for control of acute severe symptoms, for example
during the peak of the pollen season. If treatment failure
continues, the diagnosis should be revisited in the ﬁrst instance,
while surgery or immunotherapy may be subsequent treatment
options.
It seems likely that the use of INCS/AZE (single device) may be
an additional treatment option prior to immunotherapy. Immu-
notherapy may be appropriate for some patients with persistent
symptoms predominantly due to one allergen such as grass
pollen. However, many patients are polysensitised and will remain
symptomatic despite immunotherapy; these patients should
receive symptomatic treatment in addition to immunotherapy.
Relapse following successful immunotherapy treatment may
occur; for these patients further treatment options including
symptomatic treatment may be considered.
DISCUSSION
Achieving adequate symptom control is pivotal to successful AR
management and may be attained though the stepwise treatment
algorithm outlined here. Correct administration technique for INCS
and good compliance with treatment regimen are essential to
achieve symptom control, and should be checked in the event of
early treatment failures. In primary care, following treatment
failure on INCS the consensus panel does not recommend
increasing the dose of INCS, for which there is little evidence
due to the recognised ceiling effect.47 In addition, switching INCS
is also not recommended as all have comparable efﬁcacy.52–54 The
panel recommends prescription of INCS/ AZE (single device) as the
evidence-based option,46–49 rather than adding oral AH to INCS, as
there is lack of consistent evidence for the additive efﬁcacy of the
latter.21,45 The consensus panel judge that positioning INCS/AZE
(single device) as a second-line intervention in the primary care
pathway may provide value to the health service by averting
repeat GP visits (at £45 per consultation)27 or costly secondary
care referrals (at approximate costs of £136 for ENT referral, and
£212 for paediatric referral).55 The fundamentals presented in this
consensus article should apply in most health-care settings,
although obviously different patterns of allergen exposure and
allergens will occur, and cost considerations and pharmacother-
apy availability may differ.
Achieving adequate symptom control through efﬁcacious
prescription medication will avoid patients resorting to self-
medication with add-on over-the-counter (OTC) products, which
can lead to adverse effects with prolonged use, e.g., rhinitis
medicamentosa with repeat topical nasal decongestants such as
oxymetazoline.56 There are patients who do not tolerate the ﬁrst-
generation oral AHs available OTC (e.g., chlorpheniramine), and
the safety of drivers who self-medicate on escalating doses of
additive ﬁrst-generation oral AHs is a concern. In addition, there is
a need for alternatives to OCs for symptom relief for major life
events, such as exams and weddings. The panel considered that
OCs are positioned too early in the 2008 BSACI algorithm,1 and
should be recommended only for short-term use to gain control of
acute severe symptoms. The forthcoming update to the BSACI
guidelines is awaited with interest.
It was noted that all current guidelines take a patient down a
route of escalating treatment without taking a step back and
assessing whether treatment can be stepped down and when the
patient should be referred. Up to 50% of AR patients in primary
care are receiving step 3 treatment with polypharmacy, perhaps
inappropriately.27 A proportion of patients will not be adequately
controlled on initial therapies, and should be referred to
secondary care for conﬁrmation of diagnosis and further
investigation. They may also receive symptom-speciﬁc add-on
therapy. There is some advocacy for a step down approach to AR
management; for example, starting with INCS/AZE (single device)
in patients with previous treatment failure or resistance to
monotherapy. After a few weeks of achieving complete control,
consideration could be given to treatment reduction e.g., stepping
down to INCS alone. However, it is acknowledged that the step-
down approach is based on consensus and more data are
needed. Nonetheless, positioning INCS/AZE (single device) ﬁrst
line in secondary care with an integrated check of compliance
and technique has the potential to avert costly add-on
treatments, repeat visits and possibly the need for immunother-
apy or surgery.
CONCLUSION
With the availability of effective therapy, the majority of AR
symptoms can be treated in the primary care setting. This
guidance provides a clear pathway for AR treatment in primary
care practice that outlines a considered approach to improve the
management and control of AR symptoms and improve
compliance and patient satisfaction with therapy. Adherence with
this care pathway has the potential to limit the cost of providing
effective AR management in the UK by avoiding unnecessary
treatments, and investigations and avoiding the need for
unnecessary repeat GP visits and costly referrals to secondary
care in the majority of AR cases.
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